Target intelligence / Profile preview

Biofilm matrix polysaccharides

Molecular classification
Other
01

Overview

Biofilm matrix polysaccharides are the polysaccharide components of the extracellular polymeric substances (EPS) that form the structural and functional scaffold of microbial biofilms, working with proteins and extracellular DNA to create a cohesive, hydrated, and protective matrix.[2][4] They mediate initial surface attachment and intercellular adhesion, provide mechanical stability, and protect embedded cells from environmental stresses and host defenses, while also influencing nutrient retention and diffusion within the biofilm.[2][3][4] Polysaccharide composition is species- and strain-dependent: for example, Pseudomonas aeruginosa produces Psl, Pel, and alginate that contribute to attachment, cohesion, and architecture; Staphylococcus aureus and S. epidermidis produce poly-N-acetylglucosamine (PNAG) via the ica operon; and Vibrio cholerae produces Vibrio exopolysaccharide (VPS) encoded by vps gene clusters.[4][3][7] In Candida albicans, matrix polysaccharides include α-mannan and β-1,6-glucan forming a mannan–glucan complex, with β-1,3-glucan linked to antifungal drug resistance; these components are physically associated and contribute to biofilm-specific drug tolerance.[1] Because matrix polysaccharides are central to biofilm development and tolerance, they are investigated as therapeutic targets using antibodies against specific polymers (e.g., anti-Psl), inhibitors of polysaccharide–protein interactions (e.g., CdrA:Psl), and polysaccharide-degrading enzymes to disperse biofilms and potentiate antimicrobials.[4][6][7]

Other names
extracellular polysaccharidesexopolysaccharidesextracellular polymeric substances polysaccharide fractionEPS polysaccharidesbiofilm extracellular matrix polysaccharidesmatrix polysaccharides (biofilm)
02

Mechanism of action

Antibody-mediated neutralization of specific exopolysaccharides (e.g., anti-Psl), disrupting matrix integrity and enhancing antibiotic susceptibility[4] - Inhibition or disruption of polysaccharide–protein crosslinking (e.g., blocking CdrA:Psl binding) to reduce cohesion and stability[4] - Enzymatic degradation of matrix polysaccharides (hydrolases/lyases) to promote biofilm dispersal and increase antimicrobial penetration[6][7]

03

Biological functions

Adhesion to surfaces and intercellular cohesion within biofilms[2][4]Structural scaffolding and mechanical stability of the biofilm matrix[3][4]Protection against environmental stresses and host immune defenses[2][3]Hydration and prevention of desiccation via hydrated polymer networks[3]Nutrient storage/source and modulation of diffusion within biofilms[3]Mediation of biofilm development stages (attachment, maturation, dispersal)[3][4]
04

Disease associations

Infection (bacterial and fungal biofilm–associated disease, device-related infections)[3][4]Other
05

Safety considerations

Heterogeneity across species and strains (different polysaccharide chemistries such as Psl, Pel, alginate, PNAG, cellulose, VPS) complicates broad-spectrum targeting and may limit efficacy to specific pathogens[3][4][7]Potential for selective pressure and matrix compensation (redundant polymers or protein–polysaccharide interactions can maintain biofilm despite targeting one component)[4][7]Risk of inflammatory reactions to polysaccharide-degrading enzymes or antibodies; need for pathogen-specific diagnostics to avoid off-target effects on commensals (inference based on modality class; explicit safety data limited in sources)[6][4]
06

Interacting drugs

Monoclonal antibody against Pseudomonas aeruginosa Psl (e.g., anti-Psl mAb tested preclinically/clinically)[4]

2 more in the full profile.

07

Biomarkers

Detection/quantification of pathogen-specific matrix polysaccharides (e.g., Psl, Pel, alginate in Pseudomonas aeruginosa; PNAG in Staphylococcus spp.; VPS in Vibrio cholerae) as indicators of biofilm presence and potential therapeutic targets[3][4][7]β-1,3-glucan and mannan–glucan complex signatures in Candida albicans biofilms associated with drug resistance phenotypes[1]Proportion of polysaccharides within extracted matrix (e.g., >60% organic carbon fraction in certain species) as a matrix composition readout[5]

Beyond the preview

Go deeper on Biofilm matrix polysaccharides.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biofilm matrix polysaccharides.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call